HRTIS Share Price Performance
€1.86
0.45 (31.45%)
Price €1.86
Share Pricen/a
Herantis Pharma Oyj Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
HRTIS Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Herantis Pharma Oyj Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Mar 30, 2026
- -0.25
- 0%
- 0%
- -1.5%
About HRTIS
- Founded
- 2008
- Employees
- 13
- CEO
- WebsiteView website
Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.
